Discussion: Mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine that is often used in the treatment of inflammatory bowel disease. Common adverse reactions to mesalamine include gastrointestinal symptoms and headaches. Here we present a case of new onset pericarditis associated with recent initiation of mesalamine. Cardiovascular toxicity secondary to this drug has been rarely reported in the literature and its mechanism of action is not fully understood. Given the well-known complications of pericarditis, prompt diagnosis and immediate discontinuation of this drug is required. Most reported cases show resolution of symptoms one week after discontinuation of mesalamine. In this case, symptom progression was clinically correlated with mesalamine therapy, with resolution of his chest pain after discontinuation of the drug and adequate supportive treatment.
Conclusions: Early recognition of pericarditis is crucial to deliver prompt treatment and avoid life-threatening complications. Clinicians should be aware of the potential cardiotoxic effects of mesalamine, specifically the development of pericarditis.
To cite this abstract:Valenzuela, M; Martin, AI; Kapadia, NR . AN UNUSUAL CASE OF PERICARDITIS. Abstract published at Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev. Abstract 767. Journal of Hospital Medicine. 2017; 12 (suppl 2). https://www.shmabstracts.com/abstract/an-unusual-case-of-pericarditis/. Accessed February 25, 2020.